Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-159 |
Sentence |
denotes |
The serpin proteinase inhibitor 9 is an endogenous inhibitor of interleukin 1beta-converting enzyme (caspase-1) activity in human vascular smooth muscle cells. |
T1 |
0-159 |
Sentence |
denotes |
The serpin proteinase inhibitor 9 is an endogenous inhibitor of interleukin 1beta-converting enzyme (caspase-1) activity in human vascular smooth muscle cells. |
T2 |
160-374 |
Sentence |
denotes |
Interleukin-1beta-converting enzyme (ICE, caspase-1) regulates key steps in inflammation and immunity, by activating the proinflammatory cytokines interleukin (IL-)1beta and IL-18, or mediating apoptotic processes. |
T2 |
160-374 |
Sentence |
denotes |
Interleukin-1beta-converting enzyme (ICE, caspase-1) regulates key steps in inflammation and immunity, by activating the proinflammatory cytokines interleukin (IL-)1beta and IL-18, or mediating apoptotic processes. |
T3 |
375-547 |
Sentence |
denotes |
We recently provided evidence for the regulation of caspase-1 activity via an endogenous inhibitor expressed by human vascular smooth muscle cells (SMCs) (Schönbeck, U., M. |
T3 |
375-547 |
Sentence |
denotes |
We recently provided evidence for the regulation of caspase-1 activity via an endogenous inhibitor expressed by human vascular smooth muscle cells (SMCs) (Schönbeck, U., M. |
T4 |
548-560 |
Sentence |
denotes |
Herzberg, A. |
T4 |
548-560 |
Sentence |
denotes |
Herzberg, A. |
T5 |
561-573 |
Sentence |
denotes |
Petersen, C. |
T5 |
561-573 |
Sentence |
denotes |
Petersen, C. |
T6 |
574-588 |
Sentence |
denotes |
Wohlenberg, J. |
T6 |
574-588 |
Sentence |
denotes |
Wohlenberg, J. |
T7 |
589-602 |
Sentence |
denotes |
Gerdes, H.-D. |
T7 |
589-602 |
Sentence |
denotes |
Gerdes, H.-D. |
T8 |
603-615 |
Sentence |
denotes |
Flad, and H. |
T8 |
603-615 |
Sentence |
denotes |
Flad, and H. |
T9 |
616-624 |
Sentence |
denotes |
Loppnow. |
T9 |
616-624 |
Sentence |
denotes |
Loppnow. |
T10 |
625-630 |
Sentence |
denotes |
1997. |
T10 |
625-630 |
Sentence |
denotes |
1997. |
T11 |
631-633 |
Sentence |
denotes |
J. |
T11 |
631-633 |
Sentence |
denotes |
J. |
T12 |
634-638 |
Sentence |
denotes |
Exp. |
T12 |
634-638 |
Sentence |
denotes |
Exp. |
T13 |
639-643 |
Sentence |
denotes |
Med. |
T13 |
639-643 |
Sentence |
denotes |
Med. |
T14 |
644-659 |
Sentence |
denotes |
185:1287-1294). |
T14 |
644-659 |
Sentence |
denotes |
185:1287-1294). |
T15 |
660-740 |
Sentence |
denotes |
However, the molecular identity of this endogenous inhibitor remained undefined. |
T15 |
660-740 |
Sentence |
denotes |
However, the molecular identity of this endogenous inhibitor remained undefined. |
T16 |
741-968 |
Sentence |
denotes |
We report here that the serine proteinase inhibitor (serpin) PI-9 accounts for the endogenous caspase-1 inhibitory activity in human SMCs and prevents processing of the enzyme's natural substrates, IL-1beta and IL-18 precursor. |
T16 |
741-968 |
Sentence |
denotes |
We report here that the serine proteinase inhibitor (serpin) PI-9 accounts for the endogenous caspase-1 inhibitory activity in human SMCs and prevents processing of the enzyme's natural substrates, IL-1beta and IL-18 precursor. |
T17 |
969-1135 |
Sentence |
denotes |
Treatment of SMC lysates with anti-PI-9 antibody abrogated the caspase-1 inhibitory activity and coprecipitated the enzyme, demonstrating protein-protein interaction. |
T17 |
969-1135 |
Sentence |
denotes |
Treatment of SMC lysates with anti-PI-9 antibody abrogated the caspase-1 inhibitory activity and coprecipitated the enzyme, demonstrating protein-protein interaction. |
T18 |
1136-1248 |
Sentence |
denotes |
Furthermore, PI-9 antisense oligonucleotides coordinately reduced PI-9 expression and promoted IL-1beta release. |
T18 |
1136-1248 |
Sentence |
denotes |
Furthermore, PI-9 antisense oligonucleotides coordinately reduced PI-9 expression and promoted IL-1beta release. |
T19 |
1249-1451 |
Sentence |
denotes |
Since SMCs comprise the majority of cells in the vascular wall, and because IL-1 is implicated in atherogenesis, we tested the biological validity of our in vitro findings within human atheroma in situ. |
T19 |
1249-1451 |
Sentence |
denotes |
Since SMCs comprise the majority of cells in the vascular wall, and because IL-1 is implicated in atherogenesis, we tested the biological validity of our in vitro findings within human atheroma in situ. |
T20 |
1452-1534 |
Sentence |
denotes |
The unaffected arterial wall contains abundant and homogeneously distributed PI-9. |
T20 |
1452-1534 |
Sentence |
denotes |
The unaffected arterial wall contains abundant and homogeneously distributed PI-9. |
T21 |
1535-1748 |
Sentence |
denotes |
In human atherosclerotic lesions, however, PI-9 expression correlated inversely with immunoreactive IL-1beta, supporting a potential role of the endogenous caspase-1 inhibitor in this chronic inflammatory disease. |
T21 |
1535-1748 |
Sentence |
denotes |
In human atherosclerotic lesions, however, PI-9 expression correlated inversely with immunoreactive IL-1beta, supporting a potential role of the endogenous caspase-1 inhibitor in this chronic inflammatory disease. |
T22 |
1749-2005 |
Sentence |
denotes |
Thus, our results provide new insights into the regulation of this enzyme involved in immune and inflammatory processes of chronic inflammatory diseases, and point to an endogenous antiinflammatory action of PI-9, dysregulated in a prevalent human disease. |
T22 |
1749-2005 |
Sentence |
denotes |
Thus, our results provide new insights into the regulation of this enzyme involved in immune and inflammatory processes of chronic inflammatory diseases, and point to an endogenous antiinflammatory action of PI-9, dysregulated in a prevalent human disease. |